Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of the Nonclinical Biological Evaluation of Medical Devices Using Toxicologic Pathology Best Practices.

Advanced healthcare materials·2025
Same author

Pathology as a Core Discipline in the Biological Evaluation of Medical Devices.

International journal of toxicology·2025
Same author

Toxicologic Pathology Forum*: Opinion on Addressing Gaps in INHAND Terminology for Medical Devices-A Proposal to Add New Diagnostic Nomenclature.

Toxicologic pathology·2025
Same author

Is This Inflammation, Conjunctiva-Associated Lymphoid Tissue, or Tertiary Lymphoid Structures in These Rabbits?

Translational vision science & technology·2024
Same author

Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies.

Toxicologic pathology·2022
Same author

Corneal Dystrophy in Dutch Belted Rabbits as a Possible Model of Thiel-Behnke Subtype of Epithelial-Stromal TGFβ-Induced Corneal Dystrophy.

Toxicologic pathology·2020

Related Experiment Video

Updated: Jul 6, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Medical device regulations and testing for toxicologic pathologists.

Joann C L Schuh1

  • 1Applied Veterinary Pathobiology PLLC, Bainbridge Island, Washington 98110-3663, USA. Schuhj@bainbridge.net

Toxicologic Pathology
|March 14, 2008
PubMed
Summary

Understanding the regulatory landscape is key for biological assessments of biomaterials and medical devices. Harmonization efforts and ISO 10993 standards guide testing, with material type, use, and risk determining evaluation programs.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Related Experiment Videos

Last Updated: Jul 6, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Area of Science:

  • Biomaterials Science
  • Medical Device Regulation
  • Toxicologic Pathology

Background:

  • Medical devices are defined by their lack of chemical action or metabolism, distinguishing them from other medical products.
  • Global harmonization efforts, including the Global Harmonization Task Force and International Organization for Standardization (ISO) 10993 standards, are shaping the regulatory environment for medical device testing.
  • Regulatory awareness is fundamental for the biological assessment of biomaterials and medical devices.

Purpose of the Study:

  • To highlight the importance of the regulatory environment in the biological assessment of biomaterials and medical devices.
  • To discuss the harmonization of categorization and testing of medical devices.
  • To emphasize the expanding role of toxicologic pathologists in evaluating the safety and efficacy of medical devices.

Main Methods:

  • Review of International Organization for Standardization (ISO) 10993 standards for biological evaluation.
  • Analysis of regulatory directives and acts from different regions, including Japan and the United States.
  • Consideration of factors such as material type, intended use, and risk in designing testing programs.
  • Examination of the evolving need for expertise in materials science and bioengineering for preclinical evaluations.

Main Results:

  • ISO 10993 standards are widely accepted, though some national regulations (e.g., Japan, US) impose stricter testing requirements.
  • Testing programs for biomaterials and medical devices are based on material type, intended use, and risk assessment.
  • The growth of the medical device industry and new technologies necessitates increased involvement of toxicologic pathologists for safety and efficacy evaluations.
  • Preclinical evaluation requires an understanding of materials science and bioengineering to interpret complex biological interactions.

Conclusions:

  • A thorough understanding of the regulatory environment and biological assessment is crucial for medical devices and biomaterials.
  • Harmonization initiatives and established standards like ISO 10993 provide a framework for device evaluation.
  • The complexity of modern biomaterials and medical devices demands interdisciplinary expertise, including materials science, bioengineering, and toxicologic pathology, for comprehensive safety and efficacy assessment.